Specialty Pharmacy

Galena Biopharma had introduced ondansetron (Zuplenz) to the US market.

Sofosbuvir-based therapy offers the potential for high cure rates even in difficult-to-treat patient groups.

Toradol may limit ability of tumor cells to grow and spread.

Toxin may inhibit cell division in cancerous cells.

Generic Pulmicort Respules is approved for the treatment of asthma and to serve as prophylactic therapy in children aged 12 months to 8 years.

Study finds 80% of people with cardiovascular disease significantly underuse statins.

Results of the long-awaited Keynote 006 study prove the superiority of pembrolizumab to ipilimumab on criteria of both progression-free survival and overall survival.

Destabilized cell metabolism can lead to the creation of tumors.

Teva has voluntarily recalled 6 lots of fluorouracil (Adrucil) injection due to contamination.

Iressa blocks the activity of an enzyme responsible for regulating pathways implicated in the growth and survival of cancer cells.

Heat shock protein inhibitors may stop proteins involved in cancer cell survival.

Amino acid abundant in meat and fish could open receptors in cancer cells.

A pharmacy in Washington is recalling unexpired human and veterinary compounded drugs due to concerns about their sterility.

Study finds that $1 out of every $9 spent on health care is wasted due to non-adherence.

A relationship between hepatitis C and cancer is reinforced by data from epidemiologic research.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.

Particles are surrounded by a protective coating to release drugs in the presence of a specific tumor enzyme.

Janssen is asking the FDA to update the label of its once-daily hepatitis C virus (HCV) drug simeprevir (Olysio).

Compound reduces residual levels from infected dormant cells.

Top stories of the week on Specialty Pharmacy Times from July 20 to 24.

The FDA has expanded the indication for Amgen's carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid) and dexamethasone to treat patients with relapsed multiple myeloma who have received at least 1 prior therapy.

With biosimilars set to enter the US health care market, pharmacists will soon have new factors to consider when selecting and dispensing products.

Colonoscopy can catch tumors in a more treatable stage.

Researchers study excess fluid from swollen joints of rheumatoid arthritis.

Cholesterol-lowering drug is expected to cost between $7,000 and $12,000 annually.

Technivie with ribavirin is the first drug to demonstrate safety and efficacy in genotype 4 infections without interferon.

Sonidegib treats adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy.

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.